Showing results (1-10 of 312) with videos related to
Sort By:
Pageof 32
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 24, 2007
Melanoma vaccines in development: looking to the futureR Dummer, F O NestleTherapeutische Umschau. Revue Therapeutique|July 27, 1999
[Systemic therapy of metastatic melanoma]R Dummer, F O Nestle, G Hofbauer, et al.Therapeutische Umschau. Revue Therapeutique|October 3, 1998
[Therapy of cutaneous melanoma]R Dummer, F O Nestle, G Hofbauer, et al.The British Journal of Dermatology|June 3, 1999
Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndromeT M Fritz, M Kleinhans, F O Nestle, et al.Therapeutische Umschau. Revue Therapeutique|July 27, 1999
[Vaccination therapy of malignant melanoma]F O Nestle, A Tun Kyi, M Gilliet, et al.Schweizerische Medizinische Wochenschrift|February 22, 1997
[Current therapy concepts in cutaneous T-cell lymphomas]F O Nestle, A C Häffner, M H Schmid, et al.Dermatology (Basel, Switzerland)|October 5, 2001
Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatmentG F Hofbauer, B Kessler, W Kempf, et al.International Journal of Cancer|March 10, 2001
TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosisJ Kamarashev, S Ferrone, B Seifert, et al.Journal of Cutaneous Pathology|August 1, 1996
T-cell receptor beta variable region (V beta) usage in cutaneous T-cell lymphomas (CTCL) in comparison to normal and eczematous skinN Potoczna, W H Boehncke, F O Nestle, et al.Pageof 32